Home/Pipeline/AVTX-008

AVTX-008

Inflammatory Bowel Disease

PreclinicalActive

Key Facts

Indication

Inflammatory Bowel Disease

Phase

Preclinical

Status

Active

Company

Avalo Therapeutics

About Avalo Therapeutics

Avalo Therapeutics is a U.S.-based, clinical-stage biotechnology company with a mission to develop and commercialize targeted therapeutics for significant unmet needs in immunology and immuno-oncology. Its core strategy involves advancing a pipeline of immune-modulating assets through clinical development, aiming for proof-of-concept data and strategic partnerships. The company operates as a public entity, navigating the high-risk, high-reward landscape of drug development, with its valuation heavily influenced by clinical trial catalysts and financing events.

View full company profile

Therapeutic Areas

Immunology Immuno-oncology Rare Disease

Other Inflammatory Bowel Disease Drugs

Drug	Company	Phase	Status
DVI-001	Divamics	Preclinical	Approaching PCC selection
DVI-002	Divamics	Preclinical	Lead optimization
Turq-101	Turquoise Biotechnologies	Preclinical	Active
GS-4875	Gilead	Phase 2	Active
Function-based Consortium for IBD	PharmaBiome	Pre-clinical	Active
Galapagos Collaboration	Scipher Medicine	Discovery/Pre-clinical	Active
IBD Subclassification	Bio-Me	Research	Active
Anti-iRhom2 antibodies	SciRhom	Pre-clinical	Active
IBD Multi-omics Dataset	Ovation.io	Commercial	Active
Noa‑001	Noa Therapeutics	Preclinical	Active
Inflectra	EMS	Phase 3	Active
IW-601	ImmuneWalk Therapeutics	Preclinical	Active